Jan D Lunemann
Overview
Explore the profile of Jan D Lunemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
4075
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Behrens M, Comabella M, Lunemann J
Front Immunol
. 2025 Jan;
15():1509927.
PMID: 39776919
Genetic and environmental factors jointly determine the susceptibility to develop multiple sclerosis (MS). Improvements in the design of epidemiological studies have helped to identify consistent environmental risk associations such as...
2.
Oechtering J, Schaedelin S, Stein K, Maceski A, Melie-Garcia L, Benkert P, et al.
Neurol Neuroimmunol Neuroinflamm
. 2025 Jan;
12(2):e200361.
PMID: 39752618
Background And Objectives: Levels of activated complement proteins in the CSF are increased in people with multiple sclerosis (MS) and are associated with clinical disease severity. In this study, we...
3.
Androdias G, Lunemann J, Maillart E, Amato M, Audoin B, Bruijstens A, et al.
Brain
. 2024 Dec;
PMID: 39707906
The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs...
4.
Comabella M, Hegen H, Villar L, Rejdak K, Sao-Aviles A, Behrens M, et al.
J Neurol
. 2024 Dec;
272(1):26.
PMID: 39666032
Background And Objectives: The impact of viral infections on disease susceptibility and progression has predominantly been studied in patients with relapse-onset MS (RMS). Here, we determined immune responses to ubiquitous...
5.
Villacieros-Alvarez J, Lunemann J, Sepulveda M, Valls-Carbo A, Dinoto A, Fernandez V, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Dec;
12(1):e200340.
PMID: 39661937
Background And Objectives: The role of the complement system in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is not completely understood, and studies exploring its potential utility for diagnosis and prognosis...
6.
7.
Stascheit F, de Sousa C, Aigner A, Behrens M, Keller C, Klotz L, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Nov;
12(1):e200331.
PMID: 39602677
Background And Objectives: Biologics that target pathogenic antibodies (Abs) and their effector functions such as the complement inhibitor ravulizumab and the neonatal Fc receptor agonist efgartigimod have recently been approved...
8.
Chuquisana O, Spatola M, Dinoto A, Sepulveda M, Mariotto S, Tintore M, et al.
Brain
. 2024 Nov;
148(2):e4-e7.
PMID: 39530260
No abstract available.
9.
Terroba-Navajas P, Spatola M, Chuquisana O, Joubert B, de Vries J, Dik A, et al.
Med
. 2024 Oct;
6(2):100515.
PMID: 39393351
Background: Immunoglobulin (Ig) G4 auto-antibodies (Abs) against contactin-associated protein-like 2 (Caspr2), a transmembrane cell adhesion protein expressed in the central and peripheral nervous system, are found in patients with a...
10.
Lunemann J, Sao Aviles A, Tintore M, Midaglia L, Fissolo N, Gutierrez L, et al.
Mult Scler
. 2024 Sep;
30(11-12):1445-1454.
PMID: 39246021
Background: Infection by cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) play a prognostic role in multiple sclerosis (MS). Objectives: To explore whether humoral immune responses to HCMV and EBV at disease...